Digestive diseases and sciences · 2026
Risk Factors Associated with Recurrent Biliary Obstruction After Endoscopic Bilioduodenal Double Stenting.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sugimoto Mitsuru, Takagi Tadayuki, Suzuki Rei, Asama Hiroyuki, Shimizu Hiroshi, Sato Kentaro, Osawa Kento, Ohira Rei, Nakamura Jun, Kato Tsunetaka, Yanagita Takumi, Otsuka Mitsuru, Hikichi Takuto, Ohira Hiromasa
Аннотация
OBJECTIVE: Endoscopic bilioduodenal double stenting is sometimes necessary for patients with malignant bilioduodenal obstruction (MBDO). The patency of biliary stents is important for preventing cholangitis and continuing treatment. However, the factors that influence recurrent biliary obstruction (RBO) in patients with MBDO are not well known. This study aimed to identify the factors associated with RBO in patients who underwent endoscopic bilioduodenal double stenting.
METHODS: Patient characteristics, device use, and endoscopic treatment procedures were evaluated as possible risk factors for RBO.
RESULTS: Overall, 55 patients with MBDO underwent endoscopic bilioduodenal double stenting (transpapillary drainage, n = 35; endoscopic ultrasound-guided biliary drainage, n = 20). Multivariate analysis using a Fine and Gray competing risk model revealed that biliary stenting on the oral side of the duodenal stricture (HR 2.98; 95% CI 1.16-7.68; p = 0.023) and chemotherapy (HR 3.74; 95% CI 1.25-11.22; p = 0.018) were significantly associated with RBO.
CONCLUSION: Biliary stenting on the oral side of the duodenal stricture was associated with RBO during duodenal stenting in patients with MBDO. Although chemotherapy was also associated with RBO in the multivariable competing risk analysis, this finding should be interpreted cautiously. Careful treatment selection, including consideration of gastrojejunostomy in patients with oral-side biliary stenting, may help reduce the incidence of RBO.
METHODS: Patient characteristics, device use, and endoscopic treatment procedures were evaluated as possible risk factors for RBO.
RESULTS: Overall, 55 patients with MBDO underwent endoscopic bilioduodenal double stenting (transpapillary drainage, n = 35; endoscopic ultrasound-guided biliary drainage, n = 20). Multivariate analysis using a Fine and Gray competing risk model revealed that biliary stenting on the oral side of the duodenal stricture (HR 2.98; 95% CI 1.16-7.68; p = 0.023) and chemotherapy (HR 3.74; 95% CI 1.25-11.22; p = 0.018) were significantly associated with RBO.
CONCLUSION: Biliary stenting on the oral side of the duodenal stricture was associated with RBO during duodenal stenting in patients with MBDO. Although chemotherapy was also associated with RBO in the multivariable competing risk analysis, this finding should be interpreted cautiously. Careful treatment selection, including consideration of gastrojejunostomy in patients with oral-side biliary stenting, may help reduce the incidence of RBO.